----

|   | (a) | With      respect to Net Sales made by of Hana and/or its Affiliates only (the      “Hana Net Sales”)      of Sphingosomal Vincristine, a royalty no greater than [***] percent      ([***]%) of Hana Net Sales comprised of the sum of one or more of the      following percentages:  (i) [***] percent ([***]%) of Hana Net      Sales in consideration of Patents if the Product sold is embraced within      any Valid Claim under the Patents in the country where the Product was      sold; (ii) [***] percent ([***]%) of Hana Net Sales in consideration of,      and during any period of Product exclusivity provided by the laws of the      country where the Product was sold, including but not limited to marketing      exclusivity in the form of data exclusivity, pediatric exclusivity, and      orphan drug designation exclusivity; and (iii) [***] percent ([***]%) of      Hana Net Sales in consideration of Technology;  and |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | [Intentionally      deleted] |
|--------|-----|------------------------------|

|   | (c) | With      respect to Net Sales made by Hana’s Licensees and Sublicensees only (the      “Licensee/Sublicensee Net      Sales”) of Sphingosomal Vincristine, a royalty equal to the lesser      of (1) [***] percent ([***]%) of the royalty received by Hana on      Licensee/Sublicensee Net Sales pursuant to a License Agreement and/or      Sublicense, as applicable, and (2) the royalty rate set forth in Section      3.1.2(a) above with respect to Hana Net Sales as applied to      Licensee/Sublicensee Net Sales of Sphingosomal  Vincristine. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | [Intentionally      deleted]” |
|--------|-----|-------------------------------------|

|   | (a) | With      respect to Hana Net Sales of Sphingosomal Vinorelbine in the United      States, a royalty no greater than [***] percent ([***]%) of Hana Net Sales      comprised of the sum or one or more of the following      percentages:  (i) [***] percent ([***]%) of Hana Net Sales in      consideration of Patents if the Product sold is embraced within any Valid      Claim under the Patents in the United States; (ii) [***] percent ([***]%)      of Hana Net Sales in consideration of, and during any period of Product      exclusivity provided by the laws of the United States of America,      including but not limited to marketing exclusivity in the form of data      exclusivity, pediatric exclusivity, and orphan drug designation      exclusivity; and (iii) [***] percent ([***]%) of Hana Net Sales in      consideration of Technology; provided, however, that the total royalty      paid shall be limited to [***] percent ([***]%) on that portion of      cumulative Hana Net Sales up to [***] Dollars ($[***]), and limited to      [***] percent ([***]%) on that portion of cumulative Hana Net Sales in      excess of [***] Dollars ($[***]); |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (b) | With      respect to Hana Net Sales of Sphingosomal Vinorelbine in each country of      the Territory other than the United States, a royalty of [***] percent      ([***]%) of Hana Net Sales in consideration of Patents and Technology;      provided, however, that the total royalty paid shall be limited to [***]      percent ([***]%) on that portion of cumulative Hana Net Sales up to [***]      Dollars ($[***]), and increased to [***] percent ([***]%) on that portion      of cumulative Hana Net Sales in excess of [***] Dollars      ($[***]); |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | With      respect to Licensee/Sublicensee Net Sales of Sphingosomal Vinorelbine in      the United States, a royalty equal to the lesser of (1) [***] percent      ([***]%) of the royalty received by Hana on Licensee/Sublicensee Net Sales      in the United States pursuant to a License Agreement and/or Sublicense, as      applicable, and (2) the royalty rate set forth in Section 3.2.2(a) above      with respect to Hana Net Sales in the United States as applied to      Licensee/Sublicensee Net Sales of Sphingosomal Vinorelbine in the United      States; and |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | With      respect to Licensee/Sublicensee Net Sales of Sphingosomal Vinorelbine in      each country of the Territory other than the United States, a royalty      equal to the lesser of (1) [***] percent ([***]%) of the royalty received      by Hana on Licensee/Sublicensee Net Sales pursuant to a License Agreement      and/or Sublicense, as applicable, in each country of the Territory other      than the United States, and (2) the royalty rate set forth in Section      3.2.2(b) above with respect to Hana Net Sales in each country of the      Territory other than the United States as applied to Licensee/Sublicensee      Net Sales of Sphingosomal Vinorelbine in each country of the Territory      other than the United States.” |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | With      respect to Hana Net Sales of Sphingosomal Topotecan in the United States,      a royalty no greater than [***] percent ([***]%) of Hana Net Sales      comprised of the sum or one or more of the following      percentages:  (i) [***] percent ([***]%) of Hana Net Sales in      consideration of Patents if the Product sold is embraced within any Valid      Claim under the Patents in the United States; (ii) [***] percent ([***]%)      of Hana Net Sales in consideration of, and during any period of Product      exclusivity provided by the laws of the United States of America,      including but not limited to marketing exclusivity in the form of data      exclusivity, pediatric exclusivity, and orphan drug designation      exclusivity; and (iii) [***] percent ([***]%) of Hana Net Sales in      consideration of Technology; provided, however, that the total royalty      paid shall be limited to [***] percent ([***]%) on that portion of      cumulative Hana Net Sales up to [***] Dollars ($[***]), and limited to      [***] percent ([***]%) on that portion of cumulative Hana Net Sales in      excess of [***] Dollars ($[***]); |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | With      respect to Hana Net Sales of Sphingosomal Topotecan in each country of the      Territory other than the United States, a royalty of [***] percent      ([***]%) of Hana Net Sales in consideration of Patents and Technology;      provided, however, that the total royalty paid shall be limited to [***]      percent ([***]%) on that portion of cumulative Hana Net Sales up to [***]      Dollars ($[***]), and increased to [***] percent ([***]%) on that portion      of cumulative Hana Net Sales in excess of [***] Dollars      ($[***]); |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (c) | With      respect to Licensee/Sublicensee Net Sales of Sphingosomal Topotecan in the      United States, a royalty equal to the lesser of (1) [***] percent ([***]%)      of the royalty received by Hana on Licensee/Sublicensee Net Sales in the      United States pursuant to a License Agreement and/or Sublicense, as      applicable, and (2) the royalty rate set forth in Section 3.3.2(a) above      with respect to Hana Net Sales in the United States as applied to      Licensee/Sublicensee Net Sales of Sphingosomal Topotecan in the United      States; and |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | With      respect to Licensee/Sublicensee Net Sales of Sphingosomal Topotecan in      each country of the Territory other than the United States, a royalty      equal to the lesser of (1) [***] percent ([***]%) of the royalty received      by Hana on Licensee/Sublicensee Net Sales pursuant to a License Agreement      and/or Sublicense, as applicable, in each country of the Territory other      than the United States, and (2) the royalty rate set forth in Section      3.3.2(b) above with respect to Hana Net Sales in each country of the      Territory other than the United States as applied to Licensee/Sublicensee      Net Sales of Sphingosomal Topotecan in each country of the Territory other      than the United States.” |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (i) | negotiate      amendments to the Sublicense Agreement solely to incorporate the relevant      terms of Amendment No. 1 and this Amendment No.  2; |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (ii) | negotiate      and execute a consent agreement with the University of British Columbia      (the “UBC      Consent”) in respect of such amendments;  and |
|--------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (iii) | execute      an Amended and Restated Sublicense Agreement embodying such amendments      (the “Amended and      Restated SublicenseAgreement”). |
|--------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

| HANA      BIOSCIENCES, INC. |                                       | TEKMIRA      PHARMACEUTICALS |
|-----------------------------|--------------------------------------------|------------------------------|
|                        |                                       |                         | CORPORATION |
|                        |                                       |                         |   |   |
| By:                         | /s/ Steven R. Deitcher                     |                         | By: | /s/ Ian Mortimer |
|                        |                                       |                         |   |   |
| Name:                       | Steven R. Deitcher                         |                         | Name: | Ian Mortimer |
|                        |                                       |                         |   |   |
| Title:                      | President and Chief Executive      Officer |                         | Title: | Chief Financial  Officer |

----